Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Feb;12(1):31-5.
doi: 10.4196/kjpp.2008.12.1.31. Epub 2008 Feb 28.

Lysophosphatidylcholine Increases Ca Current via Activation of Protein Kinase C in Rabbit Portal Vein Smooth Muscle Cells

Affiliations

Lysophosphatidylcholine Increases Ca Current via Activation of Protein Kinase C in Rabbit Portal Vein Smooth Muscle Cells

Seungsoo Jung et al. Korean J Physiol Pharmacol. 2008 Feb.

Abstract

Lysophosphatidylcholine (LPC), a metabolite of membrane phospholipids by phospholipase A(2), has been considered responsible for the development of abnormal vascular reactivity during atherosclerosis. Ca(2+) influx was shown to be augmented in atherosclerotic artery which might be responsible for abnormal vascular reactivity. However, the mechanism underlying Ca(2+) influx change in atherosclerotic artery remains undetermined. The purpose of the present study was to examine the effects of LPC on L-type Ca(2+) current (I(Ca(L))) activity and to elucidate the mechanism of LPC-induced change of I(Ca(L)) in rabbit portal vein smooth muscle cells using whole cell patch clamp. Extracellular application of LPC increased I(Ca(L)) through whole test potentials, and this effect was readily reversed by washout. Steady state voltage dependency of activation or inactivation properties of I(Ca(L)) was not significantly changed by LPC. Staurosporine (100 nM) or chelerythrine (3 microM), which is a potent inhibitor of PKC, significantly decreased basal I(Ca(L)), and LPC-induced increase of I(Ca(L)) was significantly suppressed in the presence of PKC inhibitors. On the other hand, application of PMA, an activator of PKC, increased basal I(Ca(L)) significantly, and LPC-induced enhancement of I(Ca(L)) was abolished by pretreatment of the cells with PMA. These findings suggest that LPC increased I(Ca(L)) in vascular smooth muscle cells by a pathway that involves PKC, and that LPC-induced increase of I(Ca(L)) might be, at least in part, responsible for increased Ca(2+) influx in atherosclerotic artery.

Keywords: Ca2+ current; Lysophosphatidylcholine; Protein kinase C; Vascular smooth muscle.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
(A) Plot of Ca2+ currents evoked by repetitive step depolarization from -80 mV to 0 mV versus time. Horizontal bar indicates the time of LPC (1 µM), and nifedipine (1 µM) application in the bath. (B) Summary of the LPC-induced change of ICa(L). The value of LPC-induced change was expressed as % of control. Bath application of LPC increased the current amplitude to 142.6±8.4% (n=19). (C) Effect of LPC on current-voltage relations of ICa(L). ICa(L) was recorded at 10 mV increments between -50 and +60 mV from a holding potential of -80 mV. (D) Summary of voltage dependence of ICa(L) for control (○), 1 µM LPC (●), and 1 µM nifedipine. At each voltage steps, peak values of current were determined, and averaged (n=8).
Fig. 2
Fig. 2
Steady state activation and inactivation curves of ICa(L) obtained before and after LPC application. (A) Steady state activation curves of ICa(L) in control and LPC. Chord conductance (G) was measured at different membrane potentials and normalized to the maximal chord conductance (Gmax). Each data points were the means of 8 experiments and fitted using a following form of Boltzman equation; Y={1+exp[(V1/2 - V)/k]}-1, where V1/2 represents half maximal activation potential and k is slope factor. Measured V1/2 was -5.8±0.2 mV and -3.1±0.1 mV in control and LPC, respectively. (B) Steady state inactivation curves of ICa(L) in control and LPC. Current amplitudes (I) of test potential to 0 mV from different pretest potentials were normalized to the maximal current (Imax). Each data points were the means of 6 experiments. Curves were obtained from following form of Boltzman equation; Y={1+exp[(V - V1/2)/k]}-1, where V1/2 represents half maximal inactivation potential and k is slope factor. V1/2 was -31.4±1.2 mV and -30.2±1.6 mV in control and LPC, respectively.
Fig. 3
Fig. 3
Effect of PKC on LPC-induced change of ICa(L). Plot of Ca2+ currents evoked by repetitive step depolarization from -80 mV to 0 mV versus time. Temporal course of change of ICa(L) during treatment of LPC (1 µM) alone and LPC with 3 µM chelerythrine (A), or with 100 nM PMA (B). Horizontal bars indicate the time of drugs application. (C) Summary of the effect of pretreatment of staurosporine (100 nM), chelerythrine (3 µM), and PMA (100 nM) on LPC-induced change of ICa(L). Data are expressed as the % of control. Number of cells in each experimental condition is indicated in parenthesis.

Similar articles

Cited by

References

    1. Auge N, Fitoussi G, Bascand JL, Pieraggi M, Junquero D, Valet P. Mildly oxidized LDL evokes a sustained Ca2+-dependentretraction of vascular smooth muscle cells. Circ Res. 1996;79:871–880. - PubMed
    1. Chen Y, Morimoto S, Kitano S, Koh E, Fukuo K, Jiang B, Chen S, Yasuda O, Hirotani A, Ogihara T. Lysophosphatidylcholine causes Ca2+ influx, enhanced DNA synthesis and cytotoxicity incultured vascular smooth muscle cells. Atherosclerosis. 1995;112:69–76. - PubMed
    1. Clement-Chomienne O, Walsh MP, Cole WC. Antiotensin II activation of protein kinase C decreases delayed rectifier K+ current in rabbit vascular myocytes. J Physiol. 1996;495:689–700. - PMC - PubMed
    1. Cole WC, Clement-Chomienne O, Aiello EA. Regulation of 4-aminopyridine-sensitive, delayed rectifier K+ channels in vascular smooth muscle by phosphorylation. Biochem Cell Biol. 1996;74:439–447. - PubMed
    1. Cox DA, Cohen ML. Effects of oxidized low-density lipoprotein on vascular contraction and relaxation: clinical and pharmacological implications in atherosclerosis. Pharmacol Rev. 1996a;48:3–19. - PubMed